Patents by Inventor Peter Charles Tyler

Peter Charles Tyler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGENTS TO PREVENT TISSUE DAMAGE FROM CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITION OF THE GUT-DAMAGING BACTERIAL TOXINS TCDA AND TCDB
    Publication number: 20230346760
    Abstract: Methods for treating or preventing diseases and conditions associated with Clostridium difficile infection are provided. The methods effectively inhibit bacterial pathogens induced UDP-glucose hydrolysis activity with minimized damage to host tissue.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 2, 2023
    Inventors: Vern L. SCHRAMM, Ashleigh S. PAPARELLA, Peter Charles TYLER
  • Inhibitors of DNMT1 as anticancer therapeutic agents
    Patent number: 11518779
    Abstract: Provided herein are inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use for inhibiting DNA methyltransferase 1. The invention relates to compounds, pharmaceutical compositions, and methods for inhibiting DNA methyltransferase 1.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: December 6, 2022
    Assignees: Victoria Link Limited, Albert Einstein College of Medicine
    Inventors: Peter Charles Tyler, Farah Lamiable-Oulaidi, Anthony David Woolhouse, Shivali Ashwin Gulab, Karl Jürgen Shaffer, Ashna Ashneen Khan, Douglas Ronald Crump, Vern L. Schramm, Quan Du
  • Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses
    Patent number: 11186603
    Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: November 30, 2021
    Assignees: VICTORIA LINK LIMITED
    Inventors: Jeremy E. Turnbull, Andrew Munkacsi, Peter Charles Tyler, Olga Vladimirovna Zubkova
  • Treatment of helicobacter pylori infections
    Patent number: 11186575
    Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering to the subject an inhibitor of H.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: November 30, 2021
    Assignees: Alber Einslein College of Medicine, Victoria Link Limited
    Inventors: Vern L. Schramm, Shanzhi Wang, Antti Marko Haapalainen, Gary Brian Evans, Richard Hubert Furneaux, Keith Clinch, Peter Charles Tyler, Shivali Ashwin Gulab
  • INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS
    Publication number: 20210206795
    Abstract: Inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use as therapeutic agents against various cancers. The invention relates to compounds, pharmaceutical compositions, methods for inhibiting DNA methyltransferase 1, and methods for treating cancer. The inhibitors are compounds of the general formula.
    Type: Application
    Filed: July 9, 2019
    Publication date: July 8, 2021
    Inventors: Peter Charles Tyler, Farah Lamiable-Oulaidi, Anthony David Woolhouse, Shivali Ashwin Gulab, Karl Jürgen Shaffer, Ashna Ashneen Khan, Douglas Ronald Crump, Vern L. Schramm, Quan Du
  • HEPARAN SULFATE GLYCOMIMETIC COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMECEUTICAL USES
    Publication number: 20200131217
    Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.
    Type: Application
    Filed: March 23, 2017
    Publication date: April 30, 2020
    Inventors: Jeremy E. TURNBULL, Andrew MUNKACSI, Peter Charles TYLER, Olga Vladimirovna ZUBKOVA
  • Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-D]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)
    Patent number: 10227351
    Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: March 12, 2019
    Assignee: Victoria Link Limited
    Inventors: Gary Brian Evans, Peter Michael Kelly, Peter Charles Tyler
  • SALT AND POLYMORPHIC FORMS OF (3R,4S)-L-((4-AMINO-5H-PYRROLO[3,2,-D]PYRIMIDIN-7-YL)METHYL)-4(METHYLTHIOMETHYL)PYRODIN-3-OL(MTDIA)
    Publication number: 20180319803
    Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).
    Type: Application
    Filed: May 31, 2018
    Publication date: November 8, 2018
    Applicant: VICTORIA LINK LIMITED
    Inventors: Gary Brian Evans, Peter Michael Kelly, Peter Charles Tyler
  • Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)
    Patent number: 9994574
    Abstract: The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5?-methylthioadenosine phosphorylase (MTAP).
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: June 12, 2018
    Assignee: Victoria Link Limited
    Inventors: Gary Brian Evans, Peter Michael Kelly, Peter Charles Tyler
  • 3-hydroxypyrrolidine inhibitors of 5?-methylthioadenosine phosphorylase and nucleosidase
    Patent number: 9957272
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: May 1, 2018
    Assignees: Victoria Link Limited, Albert Einstein College of Medicine, Inc.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • Saccharide dendritic cluster compounds as inhibitors of BACE-1
    Patent number: 9879041
    Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit ?-secretase.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: January 30, 2018
    Assignees: Victoria Link Limited, University of Liverpool
    Inventors: Peter Charles Tyler, Olga Vladimirovna Zubkova, Jeremy E. Turnbull
  • Dendritic core compounds
    Patent number: 9828341
    Abstract: The invention relates to compounds that are useful for the preparation of dendrimer compounds, the use of these compounds for preparing dendrimers and processes for preparing the compounds.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: November 28, 2017
    Assignee: Victoria Link Limited
    Inventors: Peter Charles Tyler, Olga Vladimirovna Zubkova
  • 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
    Publication number: 20170166573
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to in 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: November 10, 2016
    Publication date: June 15, 2017
    Applicants: VICTORIA LINK LIMITED, ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1
    Publication number: 20170152279
    Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit ?-secretase.
    Type: Application
    Filed: November 28, 2013
    Publication date: June 1, 2017
    Inventors: Peter Charles Tyler, Olga Vladimirovna Zubkova, Jeremy E. Turnbull
  • Treatment and prevention of infections using coformycin analogs
    Patent number: 9522159
    Abstract: Methods and devices are disclosed for treating or preventing infections in a subject due to Pseudomonas aeruginosa using coformycin analogs and inhibitors of Pseudomonas aeruginosa 5?-methylthioadenosine deaminase (MTADA).
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: December 20, 2016
    Assignees: Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Vern L. Schramm, Peter Charles Tyler, Richard Fröhlich
  • 3-hydroxypyrrolidine inhibitors of 5?-methylthioadenosine phosphorylase and nucleosidase
    Patent number: 9493465
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: November 15, 2016
    Assignees: Victoria Link Limited, Albert Einstein College of Medicine, Inc.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • Oligosaccharide Compounds
    Publication number: 20160185881
    Abstract: The invention relates generally to oligosaccharide compounds and the use of these compounds as pharmaceuticals for treating diseases or conditions in which it is desirable to inhibit ?-secretase.
    Type: Application
    Filed: March 7, 2016
    Publication date: June 30, 2016
    Inventors: Ralf Schwörer, Jeremy E. Turnbull, Peter Charles Tyler, Olga Vladimirovna Zubkova
  • Oligosaccharide compounds
    Patent number: 9315587
    Abstract: The invention relates generally to oligosaccharide compounds and the use of these compounds as pharmaceuticals for treating diseases or conditions in which it is desirable to inhibit ?-secretase.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: April 19, 2016
    Assignees: Victoria Link Limited, The University of Liverpool
    Inventors: Ralf Schwoerer, Jeremy E. Turnbull, Peter Charles Tyler, Olga Vladimirovna Zubkova
  • Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
    Patent number: 9290501
    Abstract: The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5?-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: March 22, 2016
    Assignees: Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Vern L. Schramm, Keith Clinch, Peter Charles Tyler, Gary Brian Evans, Richard Hubert Furneaux
  • DENDRITIC CORE COMPOUNDS
    Publication number: 20150291522
    Abstract: The invention relates to compounds that are useful for the preparation of dendrimer compounds, the use of these compounds for preparing dendrimers and processes for preparing the compounds.
    Type: Application
    Filed: November 28, 2013
    Publication date: October 15, 2015
    Inventors: Peter Charles Tyler, Olga Vladimirovna Zubkova